Literature DB >> 21597934

Serum glutamine synthetase has no value as a diagnostic biomarker for Alzheimer's disease.

Yannick Vermeiren1, Nathalie Le Bastard, Christopher M Clark, Sebastiaan Engelborghs, Peter P De Deyn.   

Abstract

In order to test whether serum glutamine synthetase (GS) is of potential diagnostic value for Alzheimer's disease (AD), we set up a study to compare serum GS concentrations between AD patients and control subjects. The study population (n = 165) consisted of AD patients (n = 94) and age-matched (n = 41) and age-unmatched (n = 30) control subjects. Serum GS analysis was performed by means of ELISA. No significant differences in serum GS levels were found between the AD group and age-matched controls. Age correlated positively with serum GS concentrations in AD patients and control subjects. This study suggests that serum GS levels have no diagnostic value for AD.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21597934     DOI： 10.1007/s11064-011-0504-4

Source DB:  PubMed          Journal:  Neurochem Res        ISSN： 0364-3190            Impact factor:   3.996


  31 in total

1.  Immunoassay for serum glutamine synthetase in serum: development, reference values, and preliminary study in dementias.

Authors:  Miyoko Takahashi; Eric Stanton; J Ignacio Moreno; George Jackowski
Journal:  Clin Chem       Date:  2002-02       Impact factor: 8.327

2.  Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients.

Authors:  Nathalie Le Bastard; Judith Leurs; Walter Blomme; Peter Paul De Deyn; Sebastiaan Engelborghs
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

3.  The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.

Authors:  Ma Fei; Wang Jianghua; Miao Rujuan; Zhao Wei; Wang Qian
Journal:  J Neurol Sci       Date:  2011-03-26       Impact factor: 3.181

4.  Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease.

Authors:  C D Smith; J M Carney; P E Starke-Reed; C N Oliver; E R Stadtman; R A Floyd; W R Markesbery
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

5.  Glutamine synthetase-induced enhancement of beta-amyloid peptide A beta (1-40) neurotoxicity accompanied by abrogation of fibril formation and A beta fragmentation.

Authors:  M Y Aksenov; M V Aksenova; D A Butterfield; K Hensley; C Vigo-Pelfrey; J M Carney
Journal:  J Neurochem       Date:  1996-05       Impact factor: 5.372

6.  Oxidative modification of glutamine synthetase by amyloid beta peptide.

Authors:  M Y Aksenov; M V Aksenova; J M Carney; D A Butterfield
Journal:  Free Radic Res       Date:  1997-09

Review 7.  Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease.

Authors:  Christopher D Aluise; Renã A Sowell; D Allan Butterfield
Journal:  Biochim Biophys Acta       Date:  2008-08-07

8.  No correlation between time-linked plasma and CSF Abeta levels.

Authors:  Nathalie Le Bastard; Laetitia Aerts; Judith Leurs; Walter Blomme; Peter P De Deyn; Sebastiaan Engelborghs
Journal:  Neurochem Int       Date:  2009-08-18       Impact factor: 3.921

9.  Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

Authors:  G C Román; T K Tatemichi; T Erkinjuntti; J L Cummings; J C Masdeu; J H Garcia; L Amaducci; J M Orgogozo; A Brun; A Hofman
Journal:  Neurology       Date:  1993-02       Impact factor: 9.910

10.  Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia.

Authors:  L J Launer; K Andersen; M E Dewey; L Letenneur; A Ott; L A Amaducci; C Brayne; J R Copeland; J F Dartigues; P Kragh-Sorensen; A Lobo; J M Martinez-Lage; T Stijnen; A Hofman
Journal:  Neurology       Date:  1999-01-01       Impact factor: 9.910
View more
  1 in total

1.  ¹H- and ¹³C-NMR spectroscopy of Thy-1-APPSL mice brain extracts indicates metabolic changes in Alzheimer's disease.

Authors:  A Doert; U Pilatus; F Zanella; W E Müller; G P Eckert
Journal:  J Neural Transm (Vienna)       Date:  2015-03-06       Impact factor: 3.575
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.